Multimarker approach to evaluation of cardiac toxicity during preparative regimen and hematopoietic cell transplantation

Neoplasma

Volumn 55, Issue 6, 2008, Pages 532-537

  Horacek, J M ^a,b   Tichy, M ^a,b   Pudil, R ^a   Jebavy, L ^a,b   Zak, P ^a   Ulrychova, M ^a   Slovacek, L ^a,b   Maly, J ^a  

^a UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^b UNIVERSITY OF DEFENCE   (Czech Republic)

Author keywords

Biomarkers; Cardiac toxicity; Hematologic oncology; Preparative regimen; Transplantation

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CREATINE KINASE MB; CYCLOPHOSPHAMIDE; FATTY ACID BINDING PROTEIN; TROPONIN; BIOLOGICAL MARKER; MYELOABLATIVE AGENT;

ACUTE LEUKEMIA; ADULT; ARTICLE; CARDIOTOXICITY; CELL TRANSPLANTATION; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; FOLLOW UP; HEMATOPOIETIC CELL; HUMAN; MALE; ACUTE DISEASE; CHEMICALLY INDUCED DISORDER; HEART DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LEUKEMIA; MIDDLE AGED;

ACUTE DISEASE; ADULT; BIOLOGICAL MARKERS; CYCLOPHOSPHAMIDE; FEMALE; HEART DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS;

EID: 59749105879     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. SHAN K, LINCOFF AM, YOUNG JB. Anthracycline-induced cardiotoxicity. Ann Intern Med 1996; 125: 47-58.
2. JONES RL, SWANTON C, EWER MS. Anthracycline cardiotoxicity. Expert Opin Drug Saf 2006; 5: 791-809.
3. GOTTDIENER JS, APPELBAUM FR, FERRANS et al. Cardiotoxicity associated with high dose cyclophosphamide therapy. Arch Intern Med 1981; 141: 758-763. (Pubitemid 11120879)
4. GOLDBERG MA, ANTIN JH, GUINAN EC et al. Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood 1986; 68: 1114-1118. (Pubitemid 17186389)
5. MORANDI P, RUFFINI PA, BENVENUTO GM et al. Cardiac toxicity of high-dose chemotherapy. Bone Marrow Transplant 2005; 35: 323-334.
6. YEH ET, TONG AT, LENIHAN DJ et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis and management. Circulation 2004; 109: 3122-3131.
7. GANZ WI, SRIDHAR KS, GANZ SS et al. Review of tests for monitoring doxorubicin-induced cardiomyopathy. Oncology 1996; 53: 461-470.
8. MEINARDI MT, VAN DER GRAAF WT, van VELDHUISEN DJ et al. Detection of anthracycline-induced cardiotoxicity. Cancer Treat Rev 1999; 25: 237-247.
9. SPARANO JA, BROWN DL, WOLFF AC. Predicting cancer therapy-induced cardiotoxicity. The role of troponins and other markers. Drug Saf 2002; 25: 301-311.
10. YASUE H, YOSHIMURA M, SUMIDA H et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994; 90: 195-203.
11. SWEDBERG K, CLELAND J, DARGIE H et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26: 1115-1140.
12. CLERICO A, FONTANA M, ZYW L et al. Comparison of the diagnostic accuracy of brain natriuretic peptide (BNP) and the N-terminal part of the propeptide of BNP immunoassays in chronic and acute heart failure: a systematic review. Clin Chem 2007; 53: 813-822.
13. COWIE MR, JOURDAIN P, MAISEL A et al. Clinical application of B-type natriuretic peptide (BNP) testing. Eur Heart J 2003; 24: 1710-1718. (Pubitemid 37236859)
14. HESS G, RUNKEL S, ZDUNEK D et al. N-terminal probrain natriuretic peptide (NT-proBNP) in healthy blood donors and in patients from general practitioners with and without a diagnosis of cardiac disease. Clin Lab 2005; 51: 167-172.
15. URBANOVA D, URBAN L, CARTER A et al. Cardiac troponins - biochemical markers of cardiac toxicity after cytostatic therapy. Neoplasma 2006; 53: 183-190.
16. GERTZ MA. Troponin in hematologic oncology. Leuk Lymphoma 2008; 49: 194-203.
17. PEETZ D, POST F, SCHINZEL H et al. Glycogen phosphorylase BB in acute coronary syndromes. Clin Chem Lab Med 2005; 43: 1351-1358.
18. AZZAZY HM, PELSERS MM, CHRISTENSON RH. Unbound free fatty acids and heart-type fatty acid-binding protein: diagnostic assays and clinical applications. Clin Chem 2006; 52: 19-29.
19. O'DONOGHUE M, DE LEMOS JA, MORROW DA et al. Prognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes. Circulation 2006; 114: 550-557. (Pubitemid 44199644)
20. APPLE FS, WU AH, MAIR J et al. Committee on Standardization of Markers of Cardiac Damage of the IFCC. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem 2005; 51: 810-824.
21. JONES RL, SWANTON C, EWER MS. Anthracycline cardiotoxicity. Expert Opin Drug Saf 2006; 5: 791-809.
22. SANDRI MT, SALVATICI M, CARDINALE D et al. N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? Clin Chem 2005; 51: 1405-1410.
23. SNOWDEN JA, HILL GR, HUNT P et al. Assessment of cardiotoxicity during haemopoietic stem cell transplantation with plasma brain natriuretic peptide. Bone Marrow Transplant 2000; 26: 309-313.
24. NIWA N, WATANABE E, HAMAGUCHI M et al. Early and late elevation of plasma atrial and brain natriuretic peptides in patients after bone marrow transplantation. Ann Hematol 2001; 80: 460-465.
25. KUITTINEN T, JANTUNEN E, VANNINEN E et al. Cardiac effects within 3 months of BEAC high-dose therapy in non-Hodgkin's lymphoma patients undergoing autologous stem cell transplantation. Eur J Haematol 2006; 77: 120-127.
26. HORACEK JM, PUDIL R, TICHY M et al. The use of biochemical markers in cardiotoxicity monitoring in patients treated for leukemia. Neoplasma 2005; 52: 430-434. (Pubitemid 41406693)
27. FINK FM, GENSER N, FINK C et al. Cardiac troponin T and creatine kinase MB mass concentrations in children receiving anthracycline chemotherapy. Med Pediatr Oncol 1995; 25: 185-189.
28. MISSOV E, CALZOLARI C, DAVY JM et al. Cardiac troponin I in patients with hematologic malignancies. Coron Artery Dis 1997; 8: 537-541. (Pubitemid 27507672)
29. CARDINALE D, SANDRI MT, MARTINONI A et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 2000; 36: 517-522.
30. SANDRI MT, CARDINALE D, ZORZINO L et al. Minor increases in plasma troponin I predict decreased left ventricular ejection fraction after high-dose chemotherapy. Clin Chem 2003; 49: 248-252.
31. CARDINALE D, SANDRI MT, COLOMBO A et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004; 109: 2749-2754.
32. AUNER HW, TINCHON C, BREZINSCHEK RI et al. Monitoring of cardiac function by serum cardiac troponin T levels, ventricular repolarization indices, and echocardiography after conditioning with fractionated total body irradiation and highdose cyclophosphamide. Eur J Haematol 2002; 69: 1-6.
33. 2) cyclophosphamide. Bone Marrow Transplant 2001; 28: 277-282.
34. MAIR J. Glycogen phosphorylase isoenzyme BB to diagnose ischaemic myocardial damage. Clin Chim Acta 1998; 272: 79-86.